

Robert J Kurman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11042551/publications.pdf>

Version: 2024-02-01

264
papers

39,367
citations

1097

112
h-index

2680

193
g-index

272
all docs

272
docs citations

272
times ranked

18020
citing authors

#	ARTICLE	IF	CITATIONS
1	The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. American Journal of Surgical Pathology, 2010, 34, 433-443.	2.1	1,503
2	Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology, The, 2005, 6, 271-278.	5.1	1,400
3	Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study. Gynecologic Oncology, 1991, 40, 55-65.	0.6	1,226
4	The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer, 1985, 56, 403-412.	2.0	1,166
5	Ovarian Tumorigenesis. American Journal of Pathology, 2004, 164, 1511-1518.	1.9	1,107
6	Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer "Shifting the paradigm. Human Pathology, 2011, 42, 918-931.	1.1	932
7	Human Papillomavirus Infection of the Cervix. Obstetrics and Gynecology, 1992, 79, 328-337.	1.2	766
8	Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma. Journal of the National Cancer Institute, 2003, 95, 484-486.	3.0	762
9	A Clinicopathologic Analysis of 109 Cases with Emphasis on Distinguishing Pathologic Features, Site of Origin, Prognosis, and Relationship to "Pseudomyxoma Peritonei". American Journal of Surgical Pathology, 1995, 19, 1390-1408.	2.1	753
10	The Dualistic Model of Ovarian Carcinogenesis. American Journal of Pathology, 2016, 186, 733-747.	1.9	717
11	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years. Journal of Infectious Diseases, 2009, 199, 926-935.	1.9	528
12	Identifying Women With Cervical Neoplasia. JAMA - Journal of the American Medical Association, 1999, 281, 1605-10.	3.8	507
13	Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. Journal of the National Cancer Institute, 2010, 102, 325-339.	3.0	493
14	Ovarian Low-grade and High-grade Serous Carcinoma. Advances in Anatomic Pathology, 2009, 16, 267-282.	2.4	477
15	The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin. International Journal of Gynecological Pathology, 2004, 23, 41-44.	0.9	457
16	Endodermal sinus tumor of the ovary. A clinical and pathologic analysis of 71 cases. Cancer, 1976, 38, 2404-2419.	2.0	430
17	p16INK4a Immunohistochemistry Improves Interobserver Agreement in the Diagnosis of Cervical Intraepithelial Neoplasia. American Journal of Surgical Pathology, 2002, 26, 1389-1399.	2.1	425
18	Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Modern Pathology, 2011, 24, 1248-1253.	2.9	417

#	ARTICLE	IF	CITATIONS
19	Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. American Journal of Obstetrics and Gynecology, 1995, 172, 946-954.	0.7	414
20	Primary and Metastatic Mucinous Adenocarcinomas in the Ovaries. American Journal of Surgical Pathology, 2003, 27, 985-993.	2.1	407
21	Interim Guidelines for Management of Abnormal Cervical Cytology. JAMA - Journal of the American Medical Association, 1994, 271, 1866.	3.8	405
22	Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?. American Journal of Surgical Pathology, 2010, 34, 1407-1416.	2.1	395
23	Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis. American Journal of Surgical Pathology, 2005, 29, 218-224.	2.1	388
24	Pathogenesis of Ovarian Cancer. International Journal of Gynecological Pathology, 2008, PAP, 151-60.	0.9	385
25	Progestin Treatment of Atypical Hyperplasia and Well-Differentiated Carcinoma of the Endometrium in Women Under Age 40. Obstetrics and Gynecology, 1997, 90, 434-440.	1.2	383
26	Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 2006, 24, 5571-5583.	1.7	380
27	Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators. Human Pathology, 2000, 31, 539-557.	1.1	373
28	Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes and Control, 2009, 20, 449-457.	0.8	345
29	p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis. Human Pathology, 1995, 26, 1268-1274.	1.1	337
30	Epithelioid Trophoblastic Tumor. American Journal of Surgical Pathology, 1998, 22, 1393-1403.	2.1	336
31	Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer, 2001, 92, 85-91.	2.0	332
32	TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma—evidence supporting the clonal relationship of the two lesions. Journal of Pathology, 2012, 226, 421-426.	2.1	332
33	Uterine Serous Carcinoma A Morphologically Diverse Neoplasm With Unifying Clinicopathologic Features. American Journal of Surgical Pathology, 1992, 16, 600-610.	2.1	324
34	Diverse Tumorigenic Pathways in Ovarian Serous Carcinoma. American Journal of Pathology, 2002, 160, 1223-1228.	1.9	320
35	Micropapillary Serous Carcinoma of the Ovary. American Journal of Surgical Pathology, 1996, 20, 1319-1330.	2.1	309
36	Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer, 1982, 49, 2547-2559.	2.0	301

#	ARTICLE	IF	CITATIONS
37	Subclassification of Serous Borderline Tumors of the Ovary into Benign Malignant Types. American Journal of Surgical Pathology, 1996, 20, 1331-1345.	2.1	289
38	Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation. Human Pathology, 1995, 26, 1260-1267.	1.1	284
39	The Pathology of Intermediate Trophoblastic Tumors and Tumor-like Lesions. International Journal of Gynecological Pathology, 2001, 20, 31-47.	0.9	277
40	Pseudomyxoma peritonei in women: A clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Human Pathology, 1995, 26, 509-524.	1.1	258
41	Notch3 Gene Amplification in Ovarian Cancer. Cancer Research, 2006, 66, 6312-6318.	0.4	257
42	Evaluation of Diagnostic Criteria and Behavior of Ovarian Intestinal-Type Mucinous Tumors. American Journal of Surgical Pathology, 1999, 23, 617-635.	2.1	253
43	Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma. American Journal of Surgical Pathology, 2011, 35, 625-632.	2.1	251
44	Reproducibility of the Diagnosis of Endometrial Hyperplasia, Atypical Hyperplasia, and Well-Differentiated Carcinoma. American Journal of Surgical Pathology, 1998, 22, 1012-1019.	2.1	248
45	Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using an indirect immunoperoxidase technique. A new approach to classification utilizing tumor markers. Cancer, 1977, 40, 2136-2151.	2.0	245
46	The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years. Journal of Infectious Diseases, 2009, 199, 936-944.	1.9	243
47	Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology, 2013, 62, 44-58.	1.6	238
48	Basaloid and Warty Carcinomas of the Vulva. American Journal of Surgical Pathology, 1993, 17, 133-145.	2.1	235
49	Clear-Cell Adenocarcinoma of the Genital Tract in Young Females. New England Journal of Medicine, 1972, 287, 1259-1264.	13.9	225
50	Human Papillomavirus Type-Distribution in Vulvar and Vaginal Cancers and Their Associated Precursors. Obstetrics and Gynecology, 2009, 113, 917-924.	1.2	225
51	Intermediate trophoblast: a distinctive form of trophoblast with specific morphological, biochemical and functional features. Placenta, 1984, 5, 349-369.	0.7	223
52	Embryonal carcinoma of the ovary. A clinicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adult testis. Cancer, 1976, 38, 2420-2433.	2.0	222
53	Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Human Pathology, 1998, 29, 551-558.	1.1	218
54	Minimal Uterine Serous Carcinoma. American Journal of Surgical Pathology, 2000, 24, 797-806.	2.1	217

#	ARTICLE	IF	CITATIONS
55	Immunohistochemical Evidence Supporting the Appendiceal Origin of Pseudomyxoma Peritonei in Women. <i>International Journal of Gynecological Pathology</i> , 1997, 16, 1-9.	0.9	214
56	Trophoblastic pseudotumor of the uterus. An exaggerated form of "syncytial endometritis" simulating a malignant tumor. <i>Cancer</i> , 1976, 38, 1214-1226.	2.0	207
57	Toward Objective Quality Assurance in Cervical Cytopathology: Correlation of Cytopathologic Diagnoses with Detection of High-risk Human Papillomavirus Types. <i>American Journal of Clinical Pathology</i> , 1994, 102, 182-187.	0.4	200
58	Intrauterine progesterone treatment of early endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 186, 651-657.	0.7	200
59	Analysis of individual cervical human papillomavirus types in neolasia: A possible role for type 18 in rapid progression. <i>American Journal of Obstetrics and Gynecology</i> , 1988, 159, 293-296.	0.7	197
60	In situ and invasive vulvar cancer incidence trends (1973 to 1987). <i>American Journal of Obstetrics and Gynecology</i> , 1992, 166, 1482-1485.	0.7	193
61	Probable Nonpapillomavirus Etiology of Squamous Cell Carcinoma of the Vulva in Older Women. <i>International Journal of Gynecological Pathology</i> , 1991, 10, 107-125.	0.9	189
62	Immunocytochemical Localization of Placental Lactogen and Chorionic Gonadotropin in the Normal Placenta and Trophoblastic Tumors, with Emphasis on Intermediate Trophoblast and the Placental Site Trophoblastic Tumor. <i>International Journal of Gynecological Pathology</i> , 1984, 3, 101-121.	0.9	187
63	The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A gynecologic oncology group study. <i>Cancer</i> , 1995, 75, 81-86.	2.0	187
64	Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors. <i>Cancer Research</i> , 2004, 64, 6915-6918.	0.4	186
65	Low-grade serous carcinomas of the ovary contain very few point mutations. <i>Journal of Pathology</i> , 2012, 226, 413-420.	2.1	186
66	Cytokeratins 7 and 20, Dpc4, and MUC5AC in the Distinction of Metastatic Mucinous Carcinomas in the Ovary From Primary Ovarian Mucinous Tumors: Dpc4 Assists in Identifying Metastatic Pancreatic Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2002, 21, 391-400.	0.9	185
67	Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 351-356.	0.7	178
68	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	178
69	Mesenchymal tumors of the uterus VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma. A clinical and pathologic analysis of 26 cases. <i>Cancer</i> , 1976, 37, 1853-1865.	2.0	176
70	Histologic Alterations in Endometrial Hyperplasia and Well-differentiated Carcinoma Treated With Progestins. <i>American Journal of Surgical Pathology</i> , 2007, 31, 988-998.	2.1	172
71	Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. <i>Nature Communications</i> , 2017, 8, 990.	5.8	169
72	Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas. <i>Cancer Research</i> , 2009, 69, 4036-4042.	0.4	166

#	ARTICLE	IF	CITATIONS
73	Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. <i>Cancer Biology and Therapy</i> , 2006, 5, 779-785.	1.5	165
74	Diagnostic Criteria and Behavior of Ovarian Seromucinous (Endocervical-Type Mucinous and Mixed) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.1	164
75	Atypical glandular cells of undetermined significance (AGUS): Cytopathologic features, histopathologic results, and human papillomavirus DNA detection. <i>Human Pathology</i> , 1999, 30, 816-825.	1.1	161
76	Pathologic models to predict outcome for women with endometrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage--A gynecologic oncology group study. <i>Cancer</i> , 1996, 77, 1115-1121.	2.0	160
77	The Morphologic Spectrum of Ovarian Metastases of Appendiceal Adenocarcinomas. <i>American Journal of Surgical Pathology</i> , 1997, 21, 1144-1155.	2.1	159
78	Immunoperoxidase localization of papillomavirus antigens in cervical dysplasia and vulvar condylomas. <i>American Journal of Obstetrics and Gynecology</i> , 1981, 140, 931-935.	0.7	157
79	The Behavior of Serous Tumors of Low Malignant Potential. <i>International Journal of Gynecological Pathology</i> , 1993, 12, 120-127.	0.9	157
80	Heterogeneous Etiology of Squamous Carcinoma of the Vulva. <i>Obstetrics and Gynecology</i> , 1996, 87, 59-64.	1.2	157
81	Cofactors With Human Papillomavirus in a Population-Based Study of Vulvar Cancer. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1516-1523.	3.0	155
82	Interobserver and Intraobserver Variability of a Two-tier System for Grading Ovarian Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1168-1174.	2.1	152
83	Clear cell carcinoma of the endometrium. An analysis of 21 cases. <i>Cancer</i> , 1976, 37, 872-882.	2.0	151
84	Malignant germ cell tumors of the ovary. <i>Human Pathology</i> , 1977, 8, 551-564.	1.1	151
85	Diagnosis of Serous Tubal Intraepithelial Carcinoma Based on Morphologic and Immunohistochemical Features. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1766-1775.	2.1	151
86	Loss of ARID1A Expression Is an Early Molecular Event in Tumor Progression From Ovarian Endometriotic Cyst to Clear Cell and Endometrioid Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1310-1315.	1.2	148
87	p63 Expression Is Useful in the Distinction of Epithelioid Trophoblastic and Placental Site Trophoblastic Tumors by Profiling Trophoblastic Subpopulations. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1177-1183.	2.1	147
88	Refined Diagnostic Criteria for Implants Associated With Ovarian Atypical Proliferative Serous Tumors (Borderline) and Micropapillary Serous Carcinomas. <i>American Journal of Surgical Pathology</i> , 2001, 25, 419-432.	2.1	146
89	Ki-67 labeling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor, and choriocarcinoma: A double immunohistochemical staining technique using Ki-67 and Mel-CAM antibodies. <i>Human Pathology</i> , 1998, 29, 27-33.	1.1	143
90	Origin and Pathogenesis of Pelvic (Ovarian, Tubal, and Primary Peritoneal) Serous Carcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2014, 9, 27-45.	9.6	142

#	ARTICLE	IF	CITATIONS
91	Possible prognostic significance of human papillomavirus type in cervical cancer. <i>Gynecologic Oncology</i> , 1988, 29, 267-273.	0.6	141
92	HLA-G is a potential tumor marker in malignant ascites. <i>Clinical Cancer Research</i> , 2003, 9, 4460-4.	3.2	141
93	Papillary Tubal Hyperplasia. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1605-1614.	2.1	140
94	Fatty acid synthase expression in endometrial carcinoma. <i>Cancer</i> , 1998, 83, 528-537.	2.0	139
95	The Development of High-grade Serous Carcinoma From Atypical Proliferative (Borderline) Serous Tumors and Low-grade Micropapillary Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1007-1012.	2.1	139
96	Noninvasive and Invasive Micropapillary (Low-Grade) Serous Carcinoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2003, 27, 725-736.	2.1	138
97	Human papillomavirus deoxyribonucleic acid in cervical carcinoma from primary and metastatic sites. <i>American Journal of Obstetrics and Gynecology</i> , 1986, 154, 115-119.	0.7	136
98	Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 48-55.	0.9	136
99	Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14004-14009.	3.3	135
100	Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges. <i>Clinical Cancer Research</i> , 2005, 11, 7273-7279.	3.2	131
101	Shortened Telomeres in Serous Tubal Intraepithelial Carcinoma: An Early Event in Ovarian High-grade Serous Carcinogenesis. <i>American Journal of Surgical Pathology</i> , 2010, 34, 829-836.	2.1	127
102	Cystic and Adenofibromatous Clear Cell Carcinomas of the Ovary. <i>American Journal of Surgical Pathology</i> , 2009, 33, 844-853.	2.1	126
103	HLA-G Immunoreactivity Is Specific for Intermediate Trophoblast in Gestational Trophoblastic Disease and Can Serve as a Useful Marker in Differential Diagnosis. <i>American Journal of Surgical Pathology</i> , 2002, 26, 914-920.	2.1	125
104	Validation of an Algorithm for the Diagnosis of Serous Tubal Intraepithelial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 243-253.	0.9	125
105	Amplicon profiles in ovarian serous carcinomas. <i>International Journal of Cancer</i> , 2007, 120, 2613-2617.	2.3	124
106	Characterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas. <i>Clinical Cancer Research</i> , 2004, 10, 6432-6436.	3.2	121
107	A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 18739-18744.	3.3	121
108	Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1697-1703.	3.0	119

#	ARTICLE	IF	CITATIONS
109	Placental site nodule and characterization of distinctive types of intermediate trophoblast. <i>Human Pathology</i> , 1999, 30, 687-694.	1.1	118
110	Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. , 1998, 78, 41-45.		116
111	Mutational Analysis of K-ras Segregates Ovarian Serous Carcinomas into Two Types: Invasive MPSC (Low-grade Tumor) and Conventional Serous Carcinoma (High-grade Tumor). <i>International Journal of Gynecological Pathology</i> , 2003, 22, 37-41.	0.9	116
112	A Clinicopathologic Analysis of Atypical Proliferative (Borderline) Tumors and Well-Differentiated Endometrioid Adenocarcinomas of the Ovary. <i>American Journal of Surgical Pathology</i> , 2000, 24, 1465-1479.	2.1	114
113	Inactivation of the Mitogen-Activated Protein Kinase Pathway as a Potential Target-Based Therapy in Ovarian Serous Tumors with KRAS or BRAF Mutations. <i>Cancer Research</i> , 2005, 65, 1994-2000.	0.4	114
114	A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. <i>Journal of Pathology</i> , 2014, 233, 228-237.	2.1	112
115	Immunohistochemical Localization of Inhibin- α in the Placenta and Gestational Trophoblastic Lesions. <i>International Journal of Gynecological Pathology</i> , 1999, 18, 144-150.	0.9	109
116	Placental Site Nodules and Plaques A Clinicopathologic Analysis of 20 Cases. <i>American Journal of Surgical Pathology</i> , 1990, 14, 1001-1009.	2.1	108
117	The morphology, biology, and pathology of intermediate trophoblast: A look back to the present. <i>Human Pathology</i> , 1991, 22, 847-855.	1.1	107
118	Ovarian Cancer is an Imported Disease: Fact or Fiction?. <i>Current Obstetrics and Gynecology Reports</i> , 2012, 1, 1-9.	0.3	105
119	The Fallopian Tube-Peritoneal Junction. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 4-11.	0.9	101
120	Possible etiologic heterogeneity of vulvar intraepithelial neoplasia. A correlation of pathologic characteristics with human papillomavirus detection by in situ hybridization and polymerase chain reaction. <i>Cancer</i> , 1991, 67, 1599-1607.	2.0	91
121	HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2005, 96, 42-47.	0.6	90
122	Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. <i>Cancer</i> , 1992, 69, 1424-1431.	2.0	89
123	Somatic Mutations of PPP2R1A in Ovarian and Uterine Carcinomas. <i>American Journal of Pathology</i> , 2011, 178, 1442-1447.	1.9	88
124	Cyclin E and p16 Immunoreactivity in Epithelioid Trophoblastic Tumor???An Aid in Differential Diagnosis. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1105-1110.	2.1	86
125	DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma. <i>Clinical Cancer Research</i> , 2010, 16, 1997-2008.	3.2	85
126	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. <i>Journal of Pathology</i> , 2019, 248, 41-50.	2.1	84

#	ARTICLE	IF	CITATIONS
127	Immunohistochemistry of Choriocarcinoma. American Journal of Surgical Pathology, 2007, 31, 1726-1732.	2.1	80
128	Precancerous Lesions of the Cervix. , 1994, , 229-277.		77
129	Defining the Cut Point Between Low-grade and High-grade Ovarian Serous Carcinomas. American Journal of Surgical Pathology, 2009, 33, 1220-1224.	2.1	75
130	Molecular Basis of Gestational Trophoblastic Diseases. Current Molecular Medicine, 2002, 2, 1-12.	0.6	73
131	An immunohistological study of steroid localization in sertoli-leydig tumors of the ovary and testis. Cancer, 1978, 42, 1772-1783.	2.0	72
132	Cytogenetic profile of uterine sarcomas. Cancer, 1993, 71, 1283-1288.	2.0	72
133	CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Modern Pathology, 2016, 29, 1254-1261.	2.9	72
134	Ovarian Brenner tumour: A morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. European Journal of Cancer, 2013, 49, 3839-3849.	1.3	68
135	Molecular Genetic Analysis of Placental Site Trophoblastic Tumors and Epithelioid Trophoblastic Tumors Confirms Their Trophoblastic Origin. American Journal of Pathology, 2002, 161, 1033-1037.	1.9	67
136	Two Types of Ovarian Cortical Inclusion Cysts. International Journal of Gynecological Pathology, 2015, 34, 3-8.	0.9	66
137	Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. , 2000, 86, 725-730.		64
138	Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics. Journal of Oncology, 2010, 2010, 1-9.	0.6	64
139	Seromucinous Tumors of the Ovary. Whatâ€™s in a Name?. International Journal of Gynecological Pathology, 2016, 35, 78-81.	0.9	64
140	The incidence and histogenesis of vaginal adenosis. Human Pathology, 1974, 5, 265-276.	1.1	62
141	Surface Epithelial Tumors of the Ovary. , 2011, , 679-784.		62
142	Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecologic Oncology, 2019, 154, 110-117.	0.6	62
143	The role of human papillomaviruses in the pathogenesis and histologic classification of precancerous lesions of the cervix. Human Pathology, 1986, 17, 552-559.	1.1	61
144	Endometrial Carcinoma. , 1994, , 439-486.		61

#	ARTICLE	IF	CITATIONS
145	Pathology of ovarian carcinoma. Hematology/Oncology Clinics of North America, 2003, 17, 909-925.	0.9	61
146	HSD3B1 as a Novel Trophoblast-associated Marker That Assists in the Differential Diagnosis of Trophoblastic Tumors and Tumorlike Lesions. American Journal of Surgical Pathology, 2008, 32, 236-242.	2.1	57
147	Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas. American Journal of Surgical Pathology, 2017, 41, 725-737.	2.1	57
148	Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecologic Oncology, 1992, 45, 235-239.	0.6	56
149	A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: Centralized pathology review and overall survival compared with the general population. Gynecologic Oncology, 2014, 134, 267-273.	0.6	56
150	Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstetrics and Gynecology, 2000, 96, 373-379.	1.2	55
151	Salpingitis, Salpingoliths, and Serous Tumors of the Ovaries: Is There a Connection?. International Journal of Gynecological Pathology, 2002, 21, 101-107.	0.9	53
152	Molecular genetic analysis of ovarian serous cystadenomas. Laboratory Investigation, 2004, 84, 778-784.	1.7	53
153	Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecologic Oncology, 2006, 100, 139-144.	0.6	52
154	Mutational analysis of <i>BRAF</i> and <i>KRAS</i> in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. Journal of Pathology, 2014, 232, 16-22.	2.1	52
155	Carcinoma and Other Tumors of the Cervix. , 1994, , 279-326.		52
156	Ki-67 Labeling Index as an Adjunct in the Diagnosis of Serous Tubal Intraepithelial Carcinoma. International Journal of Gynecological Pathology, 2012, 31, 416-422.	0.9	50
157	BRAF Mutation Is Associated With a Specific Cell Type With Features Suggestive of Senescence in Ovarian Serous Borderline (Atypical Proliferative) Tumors. American Journal of Surgical Pathology, 2014, 38, 1603-1611.	2.1	50
158	Endometrial cancer chemoprevention: Implications of diverse pathways of carcinogenesis. Journal of Cellular Biochemistry, 1995, 59, 160-164.	1.2	49
159	The Diagnostic and Biological Implications of Laminin Expression in Serous Tubal Intraepithelial Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1826-1834.	2.1	48
160	Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin. Journal of Pathology, 2015, 237, 146-151.	2.1	48
161	Histopathologic Features of Ovaries at Increased Risk for Carcinoma. International Journal of Gynecological Pathology, 1999, 18, 151-157.	0.9	47
162	Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Human Pathology, 2002, 33, 47-59.	1.1	47

#	ARTICLE	IF	CITATIONS
163	Characterization of the Immune Cell Repertoire in the Normal Fallopian Tube. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 581-591.	0.9	46
164	Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. <i>Cancer</i> , 2002, 96, 14-20.	2.0	45
165	Steroid hormone synthesis by the ovarian stroma surrounding epithelial ovarian tumors: a potential mechanism in ovarian tumorigenesis. <i>Modern Pathology</i> , 2017, 30, 563-576.	2.9	45
166	Endometrial Hyperplasia and Related Cellular Changes. , 1994, , 411-437.		44
167	Pathological characteristics of cervical adenocarcinoma in a multi-center U.S.-based study. <i>Gynecologic Oncology</i> , 2006, 103, 541-546.	0.6	43
168	Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 584.e1-584.e22.	0.7	43
169	Survival Rates for International Federation of Gynecology and Obstetrics Stage III Ovarian Carcinoma by Cell Type: A Study of 262 Unselected Patients With Uniform Pathologic Review. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 367-371.	1.2	43
170	Gestational Trophoblastic Disease and Related Lesions. , 1994, , 1049-1093.		43
171	Subdividing Ovarian and Peritoneal Serous Carcinoma Into Moderately Differentiated and Poorly Differentiated Does not Have Biologic Validity Based on Molecular Genetic and In Vitro Drug Resistance Data. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1667-1674.	2.1	42
172	Pathology of borderline (low malignant potential) ovarian tumours. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2002, 16, 499-512.	1.4	41
173	The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis. <i>Modern Pathology</i> , 2014, 27, 231-237.	2.9	41
174	Protocol for the Examination of Specimens From Patients With Carcinomas of the Cervix. <i>Archives of Pathology and Laboratory Medicine</i> , 1999, 123, 55-61.	1.2	40
175	Micropapillary Serous Carcinoma of the Ovary. <i>International Journal of Gynecological Pathology</i> , 1998, 17, 54-60.	0.9	39
176	A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: A population-based study of 4317 women diagnosed in Denmark 1978â€”2006. <i>Gynecologic Oncology</i> , 2012, 125, 655-660.	0.6	39
177	A nationwide study of ovarian serous borderline tumors in Denmark 1978â€”2002. Risk of recurrence, and development of ovarian serous carcinoma. <i>Gynecologic Oncology</i> , 2017, 144, 174-180.	0.6	39
178	Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. <i>Human Pathology</i> , 2006, 37, 1169-1175.	1.1	38
179	Vacuolated Cytotrophoblast: A subpopulation of trophoblast in the chorion laeve. <i>Placenta</i> , 1989, 10, 429-438.	0.7	37
180	The potential value of immunohistologic techniques in the classification of ovarian and testicular tumors. <i>Human Pathology</i> , 1978, 9, 417-427.	1.1	36

#	ARTICLE	IF	CITATIONS
181	Evaluation of Microinvasion and Lymph Node Involvement in Ovarian Serous Borderline/Atypical Proliferative Serous Tumors. American Journal of Surgical Pathology, 2014, 38, 743-755.	2.1	35
182	Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study. Gynecologic Oncology, 2017, 144, 571-576.	0.6	34
183	Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gynecologic Oncology, 2014, 132, 33-37.	0.6	33
184	Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. American Journal of Surgical Pathology, 2019, 43, 1462-1472.	2.1	33
185	Low-grade Serous Carcinoma of the Ovary Displaying a Macropapillary Pattern of Invasion. American Journal of Surgical Pathology, 2008, 32, 1800-1806.	2.1	32
186	Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome. Human Pathology, 2005, 36, 1049-1054.	1.1	30
187	Diagnostic potential of tumor DNA from ovarian cyst fluid. ELife, 2016, 5, .	2.8	30
188	Precursors of endometrial and ovarian carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 1-12.	1.4	29
189	Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. Modern Pathology, 2011, 24, 1139-1145.	2.9	29
190	Detection of papillomavirus common antigens in lesions of skin and mucosa. Clinics in Dermatology, 1985, 3, 56-63.	0.8	28
191	Human Papillomavirus-Specific Serologic Response in Vulvar Neoplasia. Gynecologic Oncology, 1996, 63, 200-203.	0.6	27
192	Two types of primary mucinous ovarian tumors can be distinguished based on their origin. Modern Pathology, 2020, 33, 722-733.	2.9	25
193	Benign Diseases of the Endometrium. , 1982, , 279-310.		24
194	Endometrial Carcinoma. , 1987, , 338-372.		24
195	Human papillomavirus and the pathogenesis of vulvar carcinoma. Current Opinion in Obstetrics and Gynecology, 1992, 4, 582-585.	0.9	23
196	Precursor Lesions of Endometrial Carcinoma. , 2011, , 359-391.		22
197	Diagnosis of Endometrial Biopsies and Curettings. , 2005, , .		21
198	Discovery of a Cell. International Journal of Gynecological Pathology, 2014, 33, 339-347.	0.9	19

#	ARTICLE	IF	CITATIONS
199	Precancerous Lesions of the Cervix. , 2011, , 193-252.		19
200	Endometrial Neoplasia: Hyperplasia and Carcinoma. , 1982, , 311-351.		19
201	Benign Diseases of the Endometrium. , 1994, , 367-409.		19
202	Ovarian serous borderline tumors: the citadel defended. Human Pathology, 2000, 31, 1439-1440.	1.1	18
203	Trophoblastic Neoplasms Express Fatty Acid Synthase, Which May Be a Therapeutic Target via Its Inhibitor C93. American Journal of Pathology, 2009, 175, 2618-2624.	1.9	18
204	Bokhman's dualistic model of endometrial carcinoma. Revisited. Gynecologic Oncology, 2013, 129, 271-272.	0.6	18
205	Pathologic models to predict outcome for women with endometrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage—A gynecologic oncology group study. Cancer, 1996, 77, 1115-1121.	2.0	18
206	Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins. Oncotarget, 2015, 6, 22949-22958.	0.8	17
207	Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. Modern Pathology, 2015, 28, 437-445.	2.9	16
208	Placental Site Trophoblastic Tumor—Past as Prologue. Gynecologic Oncology, 2001, 82, 413-414.	0.6	14
209	Lack of a Y-Chromosomal Complement in the Majority of Gestational Trophoblastic Neoplasms. Journal of Oncology, 2010, 2010, 1-6.	0.6	13
210	Gestational Trophoblastic Tumors and Related Tumor-Like Lesions. , 2011, , 1075-1135.		13
211	Endometrial Carcinoma. , 2011, , 394-452.		13
212	Intraepithelial carcinoma of the cervix. Cancer, 1998, 83, 2243-2246.	2.0	11
213	Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study. International Journal of Cancer, 2020, 147, 990-995.	2.3	11
214	Characterization and Comparison of Precursors of Ovarian and Endometrial Carcinoma: Parts I and II. International Journal of Surgical Pathology, 2010, 18, 181-189.	0.4	10
215	Ki-67 Index as an Ancillary Tool in the Differential Diagnosis of Proliferative Endometrial Lesions With Secretory Change. International Journal of Gynecological Pathology, 2014, 33, 114-119.	0.9	10
216	Endometrial Carcinoma. , 2019, , 473-533.		10

#	ARTICLE	IF	CITATIONS
217	Epithelial Tumors of the Ovary. , 2019, , 841-966.		10
218	Endometrial Hyperplasia and Metaplasia. , 1987, , 322-337.		10
219	Choriocarcinoma and Placental Site Trophoblastic Tumor. CPOBGYN Clinical Perspectives in Obstetrics and Gynecology, 1987, , 45-68.	0.1	8
220	Diseases of the Vagina. , 1994, , 131-183.		8
221	Comprehensive Surgical Staging in Stage 1 Clear Cell and Endometrioid Ovarian Carcinomas. International Journal of Gynecological Pathology, 2019, 38, 241-246.	0.9	7
222	Diseases of the Vagina. , 2011, , 105-154.		7
223	Papillomaviruses in Anogenital Neoplasms. , 1986, , 153-183.		6
224	Secretion of human chorionic gonadotropin and β -fetoprotein by an ovarian germ cell tumor of apparent yolk sac origin. Gynecologic Oncology, 1984, 18, 240-246.	0.6	5
225	Synchronous and Metachronous Endocervical and Ovarian Neoplasms: A Different Interpretation of HPV Data. American Journal of Surgical Pathology, 2005, 29, 1687-1689.	2.1	5
226	Endometrial Hyperplasia, Endometrial Intraepithelial Carcinoma, and Epithelial Cytoplasmic Change. , 2005, , 178-207.		5
227	Recent Advances in the Pathology of Ovarian Cancer. Clinics in Obstetrics and Gynaecology, 1983, 10, 155-185.	0.5	5
228	Detection of the human cytomegalovirus 2.0-kb immediate early gene 1 transcripts in permissive and nonpermissive infections by RNA in situ hybridization. Journal of Biomedical Science, 1997, 4, 19-27.	2.6	4
229	Precursors of Endometrial Carcinoma. , 2019, , 439-472.		4
230	Contributions of Immunocytochemistry to Gynaecological Pathology. Clinics in Obstetrics and Gynaecology, 1984, 11, 5-23.	0.5	4
231	Diseases of the Vagina. , 2019, , 131-191.		3
232	Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. International Journal of Cancer, 1998, 78, 41-45.	2.3	3
233	Pathogenesis of Gestational Trophoblastic Lesions. , 2007, , 157-166.		3
234	Germ Cell Tumors of the Ovary: Pathology, Behavior and Treatment. Cancer Treatment and Research, 1983, , 103-153.	0.2	2

#	ARTICLE	IF	CITATIONS
235	Endometrial Hyperplasia and Epithelial Cytoplasmic Change. , 1995, , 160-183.		2
236	Norethindrone Acetate and Estradiol-Induced Endometrial Hyperplasia. Obstetrics and Gynecology, 2000, 96, 373-379.	1.2	2
237	Introduction to the ISGYP Symposium on Endometrial Hyperplasia. International Journal of Gynecological Pathology, 2000, 19, 299-300.	0.9	2
238	Gestational Trophoblastic Tumors and Related Tumorlike Lesions. , 2019, , 1307-1375.		2
239	Endometrial Carcinoma. , 2019, , 261-332.		2
240	Pregnancy, Abortion, and Ectopic Pregnancy. , 2005, , 34-66.		2
241	Abnormalities of the Genital Tract Following Stilbestrol Exposure in Utero. , 1979, 66, 161-174.		2
242	Cervical HPV DNA Detection as a Predictor of a Recurrent SIL Diagnosis Among Untreated Women. Journal of Lower Genital Tract Disease, 2001, 5, 138-143.	0.9	1
243	Re. International Journal of Gynecological Pathology, 2015, 34, 304-305.	0.9	1
244	Atypical Proliferative (Borderline) Serous Tumor in the Brain. International Journal of Gynecological Pathology, 2018, 37, 52-56.	0.9	1
245	Gestational Trophoblastic Tumors and Related Tumorlike Lesions. , 2018, , 1-71.		1
246	Precursors of Endometrial Carcinoma. , 2019, , 225-259.		1
247	Endometrial Carcinoma. , 2005, , 208-248.		1
248	New Views of Ovarian Carcinoma Types: How Will This Change Practice?. , 2014, , 29-38.		1
249	Molecular Pathology of Ovarian Cancer. , 2013, , 129-149.		1
250	Endometrial Carcinoma. , 1995, , 184-218.		1
251	Other Tumors. , 1995, , 219-243.		1
252	Pregnancy, Abortion, and Ectopic Pregnancy. , 1995, , 33-62.		1

#	ARTICLE	IF	CITATIONS
253	Endometrial Carcinoma. , 2018, , 1-62.		0
254	Diseases of the Vagina. , 2018, , 1-63.		0
255	Precursors of Endometrial Carcinoma. , 2018, , 1-34.		0
256	Epithelial Tumors of the Ovary. , 2018, , 1-128.		0
257	Mesenchymal Tumors and Other Rare Neoplasms. , 2019, , 333-361.		0
258	Pregnancy, Abortion, and Ectopic Pregnancy. , 2019, , 39-73.		0
259	Is Well-Differentiated Endometrioid Carcinoma of the Ovary Indeed an Invasive Carcinoma?. American Journal of Surgical Pathology, 2001, 25, 1341-1342.	2.1	0
260	Methods of Endometrial Evaluation. , 2005, , 275-287.		0
261	Other Tumors. , 2005, , 249-274.		0
262	Methods of Endometrial Evaluation. , 1995, , 244-253.		0
263	Borderline Ovarian Tumors. American Journal of Surgical Pathology, 1998, 22, 905-906.	2.1	0
264	Epithelial Tumors of the Ovary. , 2018, , 1-128.		0